Juneja S, Matthews J, Lukeis R, Laidlaw C, Cooper I, Wolf M, Ironside P, Garson O M
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute and St. Vincent's Hospital, Melbourne, Victoria, Australia.
Leuk Lymphoma. 1997 May;25(5-6):493-501. doi: 10.3109/10428199709039037.
In this study cytogenetic findings have been correlated with prognosis in 78 previously untreated patients with non-Hodgkin's lymphoma (NHL) presenting between 1983 and 1988. The median follow-up was 7 years (range 2-9 years). There was no significant difference in the duration of survival of 33 patients with only abnormal karyotypes, 35 patients with a mixture of normal and abnormal karyotypes (AN) and 10 patients with only normal karyotypes (NN). This was true for the entire group (p = 0.6) as well as for the subsets of diffuse lymphomas (DL) and follicular lymphomas (FL) (p = 0.6 and 0.4, respectively). Monosomy 14 was the only abnormality in the entire group of patients to be associated with a statistically significant difference in survival duration (p = 0.046). Among the FL patients, trisomy 7 (p = 0.046) and trisomy 12 (p = 0.010) were associated with shorter survival. Presence of t(14;18) did not influence survival in the entire group (p = 0.16), nor in any of the histological subgroups. Among the FL patients with t(14;18), presence of additional cytogenetic abnormalities was not associated with a worse outcome. The lack of consistency of results between various studies is likely to be due to several factors and the prognostic significance of karyotypic abnormalities can only be clarified by large prospective studies employing uniform treatment policies.
在本研究中，对1983年至1988年间初治的78例非霍奇金淋巴瘤（NHL）患者的细胞遗传学结果与预后进行了相关性分析。中位随访时间为7年（范围2 - 9年）。33例仅有核型异常的患者、35例核型正常与异常混合（AN）的患者以及10例仅有核型正常（NN）的患者，其生存时间无显著差异。这在整个组（p = 0.6）以及弥漫性淋巴瘤（DL）和滤泡性淋巴瘤（FL）亚组中均成立（分别为p = 0.6和0.4）。14号染色体单体是整个患者组中唯一与生存时间存在统计学显著差异相关的异常（p = 0.046）。在FL患者中，7号染色体三体（p = 0.046）和12号染色体三体（p = 0.010）与较短生存期相关。t(14;18)的存在对整个组的生存无影响（p = 0.16），在任何组织学亚组中也无影响。在有t(14;18)的FL患者中，额外细胞遗传学异常的存在与更差的预后无关。不同研究结果缺乏一致性可能是由于多种因素，核型异常的预后意义只能通过采用统一治疗策略的大型前瞻性研究来阐明。
